VDAC2 and the BCL-2 family of proteins

Area of Science:

• Cell Biology
• Molecular Biology
• Cancer Research

Background:

• The BCL-2 protein family regulates mitochondrial apoptosis, a critical process in cell survival and death.
• Dysregulation of mitochondrial apoptosis is a hallmark of cancer, making BCL-2 family interactions a key therapeutic strategy.
• Non-BCL-2 proteins, such as Voltage Dependent Anion Channel 2 (VDAC2), are emerging as novel regulators of apoptosis and potential drug targets.

Purpose of the Study:

• To review the role of VDAC2 in regulating apoptosis, particularly its interactions with BCL-2 family proteins.
• To clarify the molecular mechanisms by which VDAC2 influences apoptosis, addressing conflicting literature findings.
• To highlight recent advancements in targeting the VDAC2-BAK interaction for cancer therapy.

Main Methods:

• Literature review focusing on VDAC2's role in apoptosis.
• Analysis of existing evidence on VDAC2 interactions with BCL-2 effector proteins BAK and BAX.
• Discussion of recent developments in VDAC2-targeted apoptosis inhibitors.

Main Results:

• VDAC2 plays a dual role in apoptosis: it is required for BAX-mediated apoptosis but inhibits BAK-mediated apoptosis.
• The precise molecular mechanisms of VDAC2's regulation of BCL-2 effector proteins are still under investigation.
• An apoptosis inhibitor targeting the VDAC2-BAK interaction has been recently developed.

Conclusions:

• VDAC2 is a critical regulator of mitochondrial apoptosis with differential effects on BAX and BAK.
• Targeting VDAC2 interactions, particularly with BAK, represents a promising strategy for cancer treatment.
• Further research into VDAC2's molecular interactions is crucial for developing effective cancer therapies.